Currently, there are 60.05M common shares owned by the public and among those 49.00M shares have been available to trade.
The company’s stock has a 5-day price change of -1.75% and 1.61% over the past three months. IMNM shares are trading 41.87% year to date (YTD), with the 12-month market performance up to 142.11% higher. It has a 12-month low price of $6.13 and touched a high of $30.96 over the same period. IMNM has an average intraday trading volume of 851.58K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.03%, 10.85%, and -1.86% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Immunome Inc (NASDAQ: IMNM) shares accounts for 79.07% of the company’s 60.05M shares outstanding.
It has a market capitalization of $911.56M and a beta (3y monthly) value of 1.79. The earnings-per-share (ttm) stands at -$7.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.62% over the week and 6.80% over the month.
Earnings per share for the fiscal year are expected to increase by 26.26%, and 28.83% over the next financial year.
Looking at the support for the IMNM, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on May 31, 2024, with the firm’s price target at $27. JP Morgan coverage for the Immunome Inc (IMNM) stock in a research note released on April 30, 2024 offered a Overweight rating with a price target of $24. Guggenheim was of a view on April 15, 2024 that the stock is Buy, while Leerink Partners gave the stock Outperform rating on January 29, 2024, issuing a price target of $30. Wedbush on their part issued Outperform rating on December 19, 2023.
